Shanghai Haohai Biological Technology Co., Ltd. Class H (6826) AI Stock Analysis

• Market Cap: HK$11.74B
• Dividend Yield: 3.94%
• Average Volume (3M): 200.71K
• Price to Earnings (P/E): 15.2
• Beta (1Y): 0.87
• Revenue Growth: -8.54%
• EPS Growth: -9.46%
• Country: HK
• Employees: 2,156
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.45
• Shares Outstanding: 38,529,240
• 10 Day Avg. Volume: 212,287
• 30 Day Avg. Volume: 200,711
• PEG Ratio: -0.53
• Price to Book (P/B): 1.05
• Price to Sales (P/S): 2.18
• P/FCF Ratio: 20.61
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 15.56
• Revenue Forecast (FY): HK$24.27B

• Rating: 74 Outperform
• Price Target: HK$30.00 ▲(11.52% Upside)

The overall stock score of 74 reflects strong financial performance and attractive valuation, which are the most significant factors. The technical analysis suggests a neutral trend, which slightly tempers the score. Missing data for 2024 financial metrics and the absence of earnings call and corporate events data limit further insights.

Shanghai Haohai Biological Technology Co., Ltd. Class H Business Overview & Revenue Model

Company Description

Shanghai Haohai Biological Technology Co., Ltd. Class H (6826) is a leading biotechnology company based in China, specializing in the research, development, production, and sale of biological and pharmaceutical products. The company's core products include ophthalmic products, medical aesthetics, orthopedic products, and anti-adhesion and hemostasis products. With a robust focus on innovation, Haohai leverages advanced biological technology to deliver high-quality medical solutions across its key sectors.

How the Company Makes Money

Shanghai Haohai Biological Technology Co., Ltd. generates revenue primarily through the sale of its diverse range of medical and pharmaceutical products. The company's key revenue streams include ophthalmic products used in eye surgeries, medical aesthetics products for cosmetic procedures, and orthopedic products for bone and joint health. Additionally, it offers anti-adhesion and hemostatic solutions used in surgical procedures. The company also benefits from strategic partnerships and collaborations with healthcare providers, research institutions, and distributors, which enhance its market presence and distribution capabilities. These partnerships, along with a strong emphasis on research and development, contribute significantly to its earnings by driving product innovation and expanding its market reach.

Shanghai Haohai Biological Technology Co., Ltd. Class H Financial Statement Overview

Summary

Shanghai Haohai Biological Technology Co., Ltd. demonstrates strong revenue growth and profitability, supported by a robust balance sheet with low leverage. However, missing data in 2024 for key metrics could pose future analytical challenges. The company should focus on maintaining operational efficiency and improving cash flow visibility.

Income Statement

The company's revenue has shown consistent growth, with a notable increase from 2022 to 2023. The gross profit margin remains strong, indicating efficient cost management. Net income has also increased, demonstrating profitability. However, there is a slight decline in EBITDA margin, which could indicate rising operational costs.

Balance Sheet

The company has a strong equity position, with liabilities being significantly lower than stockholders' equity, leading to a healthy debt-to-equity ratio. However, the absence of total assets in 2024 data makes it challenging to calculate key ratios like equity ratio and return on equity (ROE) for the latest year.

Cash Flow

Operating cash flow showed substantial growth in 2023 but is missing for 2024, which raises concerns about cash management. The free cash flow turned positive in 2023, showing improved cash efficiency. However, the lack of data for 2024 limits further analysis.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.60B	2.68B	2.63B	2.10B	1.75B	1.32B
Gross Profit	1.39B	1.87B	1.85B	1.45B	1.26B	990.42M
EBITDA	633.69M	549.05M	713.41M	447.55M	550.45M	394.80M
Net Income	395.94M	420.45M	416.12M	180.47M	352.23M	230.07M
Balance Sheet
Total Assets	7.19B	7.12B	7.11B	6.89B	6.95B	6.30B
Cash, Cash Equivalents and Short-Term Investments	2.66B	2.76B	2.75B	2.56B	2.91B	3.11B
Total Debt	439.76M	448.43M	407.95M	118.26M	105.51M	108.08M
Total Liabilities	1.30B	1.20B	1.09B	990.02M	890.07M	564.46M
Stockholders Equity	5.61B	5.58B	5.65B	5.51B	5.71B	5.49B
Cash Flow
Free Cash Flow	393.93M	283.08M	367.22M	-85.85M	70.19M	66.21M
Operating Cash Flow	622.96M	648.57M	634.45M	231.30M	342.29M	262.07M
Investing Cash Flow	-440.45M	282.28M	-376.65M	-681.82M	-148.09M	316.92M
Financing Cash Flow	-506.73M	-390.35M	-257.73M	-288.35M	-231.25M	-190.06M

Shanghai Haohai Biological Technology Co., Ltd. Class H Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 26.90
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6826, the sentiment is Positive. The current price of 26.9 is below the 20-day moving average (MA) of 27.01, below the 50-day MA of 27.08, and above the 200-day MA of 25.97, indicating a bullish trend. The MACD of 0.19 indicates Negative momentum. The RSI at 55.40 is Neutral, neither overbought nor oversold. The STOCH value of 52.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:6826.

Shanghai Haohai Biological Technology Co., Ltd. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
6826	74 Outperform	HK$11.74B	15.17	6.69%	3.94%	-8.54%	-9.46%
2315	64 Neutral	HK$11.30B	78.82	16.13%	―	48.38%	―
2171	53 Neutral	HK$9.65B	-16.79	-42.46%	―	1219.19%	25.15%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
1672	49 Neutral	HK$9.23B	-32.42	-12.74%	―	-76.58%	-4.90%
2162	41 Neutral	HK$17.69B	―	-8.79%	―	964.40%	65.90%
2157	39 Underperform	HK$11.23B	-51.69	-21.42%	―	240.05%	-140.09%

Shanghai Haohai Biological Technology Co., Ltd. Class H Corporate Events

Shanghai Haohai Biological Technology Schedules Board Meeting for Q3 Results

Shanghai Haohai Biological Technology Co., Ltd. has announced a board meeting scheduled for October 24, 2025, to consider and approve the company’s third quarterly results for the period ending September 30, 2025. This meeting is significant as it will provide insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and stakeholder interests.

The most recent analyst rating on (HK:6826) stock is a Buy with a HK$29.00 price target. To see the full list of analyst forecasts on Shanghai Haohai Biological Technology Co., Ltd. Class H stock, see the HK:6826 Stock Forecast page.

Shanghai Haohai Biological Announces Interim Dividend for 2025

Shanghai Haohai Biological Technology Co., Ltd. has announced an interim cash dividend of RMB 0.4 per share for the six-month period ending June 30, 2025. The dividend will be paid in Hong Kong dollars at an exchange rate of RMB 1 to HKD 1.096155, with a payment date set for October 17, 2025. The announcement reflects the company’s financial health and commitment to returning value to its shareholders. The dividend distribution also involves withholding tax implications for both resident and non-resident shareholders, with varying rates based on residency and applicable tax treaties.

The most recent analyst rating on (HK:6826) stock is a Buy with a HK$33.00 price target. To see the full list of analyst forecasts on Shanghai Haohai Biological Technology Co., Ltd. Class H stock, see the HK:6826 Stock Forecast page.

Shanghai Haohai Reports Decline in Revenue and Profit for H1 2025

Shanghai Haohai Biological Technology Co., Ltd. reported a decrease in revenue and profit for the six-month period ending June 30, 2025, compared to the same period in 2024. Revenue fell by approximately 7.48% to RMB1,292.64 million, while profit attributable to ordinary equity holders decreased by 10.29% to RMB211.07 million. Despite these declines, the company maintained its interim dividend at RMB0.40 per share. The decrease in R&D expenses by 21.53% and a slight improvement in other income and gains were notable financial movements during the period.

The most recent analyst rating on (HK:6826) stock is a Buy with a HK$33.00 price target. To see the full list of analyst forecasts on Shanghai Haohai Biological Technology Co., Ltd. Class H stock, see the HK:6826 Stock Forecast page.

Shanghai Haohai Announces 2025 Interim Dividend Distribution

Shanghai Haohai Biological Technology Co., Ltd. has announced the distribution and payment of an interim dividend for 2025, amounting to RMB0.40 per share, totaling RMB91,493,200.00. The dividend will be distributed to H Shareholders in Hong Kong Dollars, with payments scheduled for October 17, 2025. The company has also outlined tax arrangements for non-resident enterprise shareholders and individual holders of H shares, ensuring compliance with the Enterprise Income Tax Law of the People’s Republic of China.

The most recent analyst rating on (HK:6826) stock is a Buy with a HK$33.00 price target. To see the full list of analyst forecasts on Shanghai Haohai Biological Technology Co., Ltd. Class H stock, see the HK:6826 Stock Forecast page.

Shanghai Haohai Biological Technology Schedules Board Meeting for Interim Results

Shanghai Haohai Biological Technology Co., Ltd. has announced that its board of directors will meet on August 22, 2025, to review and approve the interim results for the first half of the year ending June 30, 2025. The meeting will also consider the possibility of declaring an interim dividend, which could impact shareholder returns and reflect the company’s financial health.